QUOTED. May 15, 2018. Thomas Rodgers.
Liquid biopsy marquee player Grail Inc. has reported results of several proof-of-concept approaches to cancer screening that achieved high specificity, and a handful of smaller-scale cancer-specific tests are already available. See what Thomas Rodgers of Grail investor McKesson Ventures had to say about it here.
"If with a simple annual blood test someone who feels completely healthy could identify that they might have an early-stage malignant tumor, that would obviously be revolutionary." –Thomas Rodgers, senior VP and managing director, McKesson Ventures
- Find out more: Market Intel: Liquid Biopsies For Cancer Screening – Far From Reach Or Close At Hand?
Click here for a free trial of Medtech Insight